Indicated for: prevention of Japanese encephalitis
Route of administration: intramuscular
Substance: Japanese encephalitis vaccine (inactive, adsorbed) (vaccine)
ATC: J07BA02 (Antiinfectives for systemic use | Viral vaccines | Encephalitis vaccines)
The Japanese encephalitis vaccine (inactivated, adsorbed) is used to prevent Japanese encephalitis, a severe viral disease transmitted by the bite of infected Culex mosquitoes. The Japanese encephalitis virus is endemic in many parts of Asia and the Pacific, and the disease can cause severe brain inflammation, with risks of death or long-term neurological complications.
The vaccine contains inactivated viruses and is administered intramuscularly, usually in two doses, 28 days apart. It is recommended for individuals traveling to or living in endemic areas, as well as those working in laboratories with potential exposure to the virus.
Common side effects include pain at the injection site, mild fever, headache, and fatigue. In rare cases, severe allergic reactions may occur.
The Japanese encephalitis vaccine (inactivated, adsorbed) is an essential measure for protecting against this potentially fatal disease, helping to reduce the risk of outbreaks and safeguard public health.